DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Phase 2

Terminated

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: ENTO
Drug: Placebo

First Posted Date: 2016-03-08

Last Posted Date: 2018-12-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 66

Registration Number: NCT02701634

Locations: 🇫🇷
Hopital Saint Louis, Paris Cedex 10, France
🇪🇸
Hospital Universitario de Salamanca, Salamanca, Spain
🇩🇪
Universitatsklinikum Frankfurt, Frankfurt am Main, Germany

and more 27 locations

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Hu5F9-G4

First Posted Date: 2016-02-09

Last Posted Date: 2019-02-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 20

Registration Number: NCT02678338

Locations: 🇬🇧
St. James University Hospital, Leeds, United Kingdom
🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
🇬🇧
The Royal Liverpool University Hospital, Liverpool, United Kingdom

and more 2 locations

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-02-02

Last Posted Date: 2019-01-08

Lead Sponsor: Gilead Sciences

Target Recruit Count: 375

Registration Number: NCT02671500

Locations: 🇻🇳
Bach Mai Hospital, Hanoi, Vietnam
🇲🇾
Hospital Tengku Ampuan Afzan, Pahang, Malaysia
🇸🇬
National University Hospital, Singapore, Singapore

and more 35 locations

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Cilofexor
Drug: Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2020-10-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 120

Registration Number: NCT02654002

Locations: 🇺🇸
SeaView Research, Inc, Miami, Florida, United States

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: B/F/TAF
Drug: E/C/F/TAF
Drug: E/C/F/TDF
Drug: ATV
Drug: RTV
Drug: FTC/TDF

First Posted Date: 2016-01-12

Last Posted Date: 2020-03-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 472

Registration Number: NCT02652624

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL/VOX
Drug: SOF/VEL

First Posted Date: 2015-12-24

Last Posted Date: 2019-03-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 333

Registration Number: NCT02639247

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL/VOX
Drug: SOF/VEL

First Posted Date: 2015-12-24

Last Posted Date: 2019-03-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 220

Registration Number: NCT02639338

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tirabrutinib
Drug: Placebo

First Posted Date: 2015-12-10

Last Posted Date: 2020-09-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 42

Registration Number: NCT02626026

Locations: 🇺🇸
Lovelace Scientific Resources, Inc., Venice, Florida, United States
🇺🇸
Center for Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

and more 6 locations

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: TDF
Drug: E/C/F/TAF
Drug: FTC
Drug: FTC/TDF
Drug: 3TC
Drug: Third agent

First Posted Date: 2015-11-30

Last Posted Date: 2020-03-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 167

Registration Number: NCT02616783

Locations: 🇫🇷
Hopital Necker les Enfants Malades, Paris, France
🇧🇪
University Hospital Gent, Ghent, Belgium
🇮🇹
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

and more 32 locations

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: E/C/F/TAF

First Posted Date: 2015-11-26

Last Posted Date: 2020-07-23

Lead Sponsor: Gilead Sciences

Target Recruit Count: 66

Registration Number: NCT02616029

Locations: 🇮🇹
ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Italy
🇫🇷
Hopital Sainte Marguerite - Hospital, Marseille, France
🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Spain

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy